Clinical Trials Using Venetoclax

Clinical trials are research studies that involve people. The clinical trials on this list are studying Venetoclax. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 76-96 of 96

  • A Study of ABBV-181 in Participants With Advanced Solid Tumors

    This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. This study will also evaluate the safety and tolerability of ABBV-181 in combination with Rovalpituzumab Tesirine and ABBV-181 in combination with venetoclax. The study will consist of 3 parts: ABBV-181 monotherapy dose escalation and expansion, ABBV-181 in combination with Rovalpituzumab Tesirine and ABBV-181 in combination with venetoclax.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

    This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab and obinutuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, obinutuzumab, and venetoclax may work better in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or Richter syndrome.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Dasatinib and Venetoclax in Treating Patients with Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

    This phase II trial studies how well dasatinib and venetoclax work in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia. Dasatinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate before Donor Stem Cell Transplant in Treating Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    This randomized phase II trial studies how well venetoclax and sequential busulfan, cladribine, and fludarabine phosphate before donor stem cell transplant work in treating patients with acute myelogenous leukemia or myelodysplastic syndrome. Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

    This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • IMGN632 as Monotherapy or With Venetoclax and / or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia

    This is an open-label, multicenter, Phase 1b / 2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and / or venetoclax in patients with relapsed and frontline CD123-positive AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with MRD+ AML after frontline treatment.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

    The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

  • A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

    JZP025-101 is an open-label, multicenter, multi-arm, nonrandomized phase 1b master trial to determine the recommended phase 2 dose (RP2D) of CPX-351 when administered in combination with various targeted agents in previously untreated subjects with Acute Myeloid Leukemia (AML) who are fit to receive intensive chemotherapy (ICT). Subjects will be assigned to treatment arms based on results of AML mutation testing.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Venetoclax and Lintuzumab-Ac225 in AML Patients

    The study is a multicenter, open label Phase I / II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed / refractory AML. (Phase 1 portion) 2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Ibrutinib and Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia after Ibrutinib Resistance

    This phase II trial studies how well the combination of ibrutinib and venetoclax works in treating patients with chronic lymphocytic leukemia whose cancer has stopped responding to ibrutinib alone. Both ibrutinib and venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ibrutinib and venetoclax together after development of ibrutinib resistance may work better than discontinuing ibrutinib and switching to other chemotherapy drugs.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Ruxolitinib and Venetoclax in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia

    This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax in treating patients with acute myeloid leukemia that has come back or has not responded to treatment. Ruxolitinib and venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This study is being done to see if the combination of ruxolitinib and venetoclax works better in treating patients with acute myeloid leukemia compared to standard of care chemotherapy.
    Location: 2 locations

  • Rituximab, Idelalisib, and Venetoclax in Treating Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia

    This phase I trial studies the best dose and side effects of idelalisib and venetoclax when given together with rituximab. Monoclonal antibodies, such as rituximab, may interfere with the ability of tumor cells to grow and spread. Idelalisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab, idelalisib and venetoclax may work better at treating chronic lymphocytic leukemia.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • A Study of Venetoclax and AMG 176 in Patients With Relapsed / Refractory Hematologic Malignancies

    This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL) / diffuse large B-cell lymphoma (DLBCL). This study will include a dose escalation phase to identify the maximum tolerated dose / recommended phase 2 dose (MTD / RPTD) of venetoclax plus AMG 176 as well as a dose expansion phase to confirm safety, explore efficacy, and confirm the suitability of the preliminary RPTD.
    Location: 5 locations

  • A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

    This study is designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in participants with relapsed or refractory (R / R) multiple myeloma (MM) who have received at least 1 prior line of therapy. The study will consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the participants will be divided into 2 cohorts, participants positive for t(11;14) translocation and participants negative for t(11;14) translocation.
    Location: 6 locations

  • A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

    This is a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.
    Location: Duke University Medical Center, Durham, North Carolina

  • Venetoclax in Combination with BEAM Chemotherapy Regimen in Treating Patients with Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

    This phase I trial studies the side effects and best dose of venetoclax when given in combination with standard chemotherapy regimen in treating patients with non-Hodgkin lymphoma undergoing stem cell transplant. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known how well venetoclax works when given with standard chemotherapy in treating patients with non-Hodgkin lymphoma undergoing stem cell transplant.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Daratumumab, Bortezomib, and Dexamethasone with or without Venetoclax in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of venetoclax when given together with daratumumab, bortezomib, and dexamethasone, and how well they work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as venetoclax and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body’s immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving venetoclax with daratumumab, bortezomib, and dexamethasone may work better in treating patients with relapsed or refractory multiple myeloma compared to standard of care treatment, including chemotherapy.
    Location: 3 locations

  • Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back. Venetoclax and ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with ixazomib citrate and dexamethasone may work better in treating patients with multiple myeloma.
    Location: 7 locations

  • Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    This phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or not responding to treatment. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving obinutuzumab, venetoclax, and lenalidomide may work better in treating patients with B-cell non-Hodgkin lymphoma.
    Location: 2 locations

  • A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies

    A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female subjects with different hematological malignancies.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire